Future work should focus on the efficacy of YAP inhibitors in combination with immune checkpoint PD-L1/PD-1 blockade in EGFR mutant NSCLC without targetable resistant mutations. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.